ReviewVaccines2017
Current Status of Rift Valley Fever Vaccine Development.
Review in Vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed.
- Potent neutralization of Rift Valley fever virus mediated by monoclonal antibodies via concurrent inhibition of attachment and fusion.Emerging microbes & infections · 2026Article
- Rift Valley Fever at Europe's Risk Frontier: Climate, Vectors, and One Health Preparedness.Veterinary sciences · 2026Review
- Climate Change, Urbanization, and the Emerging Urban Threat of Rift Valley Fever in Tropical and Subtropical Cities: A Narrative Review.Tropical medicine and infectious disease · 2026Review
- Seroprevalence of Rift Valley fever virus and factors associated with exposure in south-central Uganda.BMC infectious diseases · 2026Article
- Rift Valley fever: An emerging zoonotic threat to global health and agriculture.World journal of virology · 2026Review
- ZnNPs and senps co-adjuvants deliver superior and long-lasting protection: first report in inactivated Rift Valley fever vaccines for sheep.Tropical animal health and production · 2025Article
- Inter-epidemic seroprevalence of Rift Valley fever virus and associated risk factors in humans in Eastern Rwanda.PLoS neglected tropical diseases · 2025Article
- Detection and Molecular Characterization of Rift Valley Fever Virus in Apparently Healthy Cattle in Uganda.Pathogens (Basel, Switzerland) · 2025Article
- Has the epidemiologic conundrum of Rift Valley fever changed?Tropical animal health and production · 2025Review
- Rift Valley fever: A zoonotic disease with global potential.Open veterinary journal · 2025Review
- Article
- Article
- Rift Valley Fever in Rwanda Is Urging for Enhancing Global Health Security Through Multisectoral One Health Strategy.Microorganisms · 2025Review
- Rift Valley fever outbreak among animal handlers in Kinyogoga Village, Nakaseke District, Central Uganda: A case study.PLOS global public health · 2025Article
- A Lipid Nanoparticle-Formulated Self-Amplifying RNA Rift Valley Fever Vaccine Induces a Robust Humoral Immune Response in Mice.Vaccines · 2024Article
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- The socioeconomic impacts of Rift Valley fever: A rapid review.PLoS neglected tropical diseases · 2024Review
- Article
- Monoclonal Antibodies for Rift Valley Fever Virus Nucleocapsid: Application in IgG/IgM ELISA for Sero-Diagnosis.Pathogens (Basel, Switzerland) · 2024Article
- Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rift Valley Fever (RVF) is a mosquito-borne zoonotic disease that presents a substantial threat to human and public health. It is caused by Rift Valley fever phlebovirus (RVFV), which belongs to the genus Phlebovirus and the family Phenuiviridae within the order Bunyavirales. The wide distribution of competent vectors in non-endemic areas coupled with global climate change poses a significant threat of the transboundary spread of RVFV. In the last decade, an improved understanding of the molecular biology of RVFV has facilitated significant progress in the development of novel vaccines, including DIVA (differentiating infected from vaccinated animals) vaccines. Despite these advances, there is no fully licensed vaccine for veterinary or human use available in non-endemic countries, whereas in endemic countries, there is no clear policy or practice of routine/strategic livestock vaccinations as a preventive or mitigating strategy against potential RVF disease outbreaks. The purpose of this review was to provide an update on the status of RVF vaccine development and provide perspectives on the best strategies for disease control. Herein, we argue that the routine or strategic vaccination of livestock could be the best control approach for preventing the outbreak and spread of future disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.